Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSELLA: Relacorilant + Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT05257408Phase 3Active, not recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 14
01
Overview
A Phase 3 trial of relacorilant in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Corcept Therapeutics. Started Jun 2022; status: active, not recruiting.
02
Drugs
relacorilant
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05257408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257408.